What: Shares in Epizyme surged higher by more than 30% earlier today after the company reported positive results from a trial studying its tazemetostat in patients with non-Hodgkin lymphoma.
So What: Epizyme's phase 1 results show that 60%, or 9 out of 15, patients taking tazemetostat responded to the treatment, with two of the nine patients enjoying an ongoing complete response.
Continue Reading Below
Among those responding to treatment were five of nine patients with large B-cell lymphoma and three of five patients with follicular lymphoma.
Now What: Epizyme is a clinical-stage biotech company without any approved products on the market, so this is welcome news to investors. However, before investors get too excited they should remember that this is a phase 1 trial, not a phase 3 trial, and that tazemetostatmay not show similar efficacy in future trials that are larger in size.
Investors should also bear in mind that there were five severe or life threatening adverse events observed in this early stage trial, so there are safety considerations to digest too.
Regardless, Epizyme is an intriguing company, and this drug could have potential -- especially given that 85% of patients in this trial had received and failed on three or more previous treatments. That suggests that investors will want to keep tabs on tazemetostat'sphase 2 trials, which began enrolling patients this quarter.
The article Why Epizyme Inc. Shares Are Soaring originally appeared on Fool.com.
Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.